Clinical Trial Update: Ambroxol to Slow Progression in Parkinson Disease [Phase 3]

View source ↗

Summary

Ambroxol is being studied in a Phase 3 trial to slow progression in Parkinson disease and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Ambroxol (Ambroxol)

Snippet

Sponsor: University College, London | Conditions: Parkinson Disease | Phase 3 | Status: RECRUITING